V
35.93
0.77 (2.20%)
| Previous Close | 35.15 |
| Open | 35.17 |
| Volume | 110,177 |
| Avg. Volume (3M) | 856,580 |
| Market Cap | 2,839,841,536 |
| Price / Earnings (TTM) | 94.54 |
| Price / Earnings (Forward) | 25.38 |
| Price / Sales | 5.83 |
| Price / Book | 2.26 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2026 |
| Profit Margin | 7.13% |
| Operating Margin (TTM) | 7.03% |
| Diluted EPS (TTM) | 0.420 |
| Quarterly Revenue Growth (YOY) | 18.20% |
| Total Debt/Equity (MRQ) | 4.23% |
| Current Ratio (MRQ) | 5.10 |
| Operating Cash Flow (TTM) | 89.42 M |
| Levered Free Cash Flow (TTM) | 76.93 M |
| Return on Assets (TTM) | 1.94% |
| Return on Equity (TTM) | 2.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Veracyte, Inc. | Bullish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 3.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.0 |
| Average | 0.60 |
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.54% |
| % Held by Institutions | 107.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Guggenheim, 39.18%) | Buy |
| Median | 48.00 (33.61%) | |
| Low | 37.00 (Morgan Stanley, 2.99%) | Sell |
| Average | 45.00 (25.26%) | |
| Total | 2 Buy, 1 Sell | |
| Avg. Price @ Call | 39.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 06 Mar 2026 | 37.00 (2.99%) | Sell | 36.09 |
| Needham | 26 Feb 2026 | 48.00 (33.61%) | Buy | 38.75 |
| Guggenheim | 05 Jan 2026 | 50.00 (39.18%) | Buy | 43.63 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHAMBERS REBECCA | 38.75 | 38.75 | 47,275 | 1,831,906 |
| FEBBO PHILLIP G. | 38.75 | 38.75 | 47,320 | 1,833,650 |
| LEITE JOHN | 38.75 | 38.75 | 38,244 | 1,481,955 |
| MCGUIRE ANNIE | 38.75 | 38.75 | 40,132 | 1,555,115 |
| STAPLEY MARC | 38.75 | 38.75 | 103,233 | 4,000,279 |
| Aggregate Net Quantity | 276,204 | |||
| Aggregate Net Value ($) | 10,702,905 | |||
| Aggregate Avg. Buy ($) | 38.75 | |||
| Aggregate Avg. Sell ($) | 38.75 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FEBBO PHILLIP G. | Officer | 26 Feb 2026 | Acquired (+) | 71,806 | 38.75 | 2,782,483 |
| FEBBO PHILLIP G. | Officer | 26 Feb 2026 | Disposed (-) | 24,486 | 38.75 | 948,833 |
| MCGUIRE ANNIE | Officer | 26 Feb 2026 | Acquired (+) | 50,999 | 38.75 | 1,976,211 |
| MCGUIRE ANNIE | Officer | 26 Feb 2026 | Disposed (-) | 10,867 | 38.75 | 421,096 |
| CHAMBERS REBECCA | Officer | 26 Feb 2026 | Acquired (+) | 59,324 | 38.75 | 2,298,805 |
| CHAMBERS REBECCA | Officer | 26 Feb 2026 | Disposed (-) | 12,049 | 38.75 | 466,899 |
| LEITE JOHN | Officer | 26 Feb 2026 | Acquired (+) | 47,149 | 38.75 | 1,827,024 |
| LEITE JOHN | Officer | 26 Feb 2026 | Disposed (-) | 8,905 | 38.75 | 345,069 |
| STAPLEY MARC | Officer | 26 Feb 2026 | Acquired (+) | 139,074 | 38.75 | 5,389,118 |
| STAPLEY MARC | Officer | 26 Feb 2026 | Disposed (-) | 35,841 | 38.75 | 1,388,839 |
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 |
| 11 Jan 2026 | Announcement | Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results |
| 29 Dec 2025 | Announcement | Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |